Lack of clinically significant drug interactions between nevirapine and buprenorphine

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 30-37

  McCance Katz, Elinore F ^a,e   Moody, David E ^b   Morse, Gene D ^c   Ma, Qing ^c   Rainey, Petrie M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DRUG METABOLITE; NEVIRAPINE;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INTERACTION; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PROBABILITY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; COGNITION; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; NARCOTIC ANTAGONISTS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77149145525     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00006.x     Document Type: Article

References (36)

1. Department of Health and Human Services Centers for Disease Control and Prevention. Available at : http://www.cdc.gov/hiv/topics/surveillance/united- states.htm. Accessed May 31, 2009.
2. Available at : http://www.unaids.org/en/PolicyAndPractice/KeyPopulations/ InjectDrugUsers/. Accessed June 4, 2009.
3. Ball J, Corty E, Bond H, et al. The reduction of intravenous heroin use, non-opiate abuse, and crime during methadone maintenance treatment: Further findings. NIDA Res Monogr. 1988 81 : 224 230.
4. McCance-Katz EF. Office based treatment of opioid dependence with buprenorphine. Harv Rev Psychiatry. 2004 12 : 321 338.
5. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr. 2003 34 (Suppl 1 S8 14.
6. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic. Am J Med. 1992 92 : 495 502.
7. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. AIDS. 2002 16 : 2175 2182.
8. McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict. 2002 11 : 271 278.
9. McCance-Katz EF. Treatment of opioid dependence and HIV/HCV co-infection in opioid dependent patients: The importance of drug interactions between opioids and antiretroviral medications. Clin Infect Dis. 2005 41 : S89 95.
10. McCance-Katz EF, Moody DE, Morse G, et al. Interactions between buprenorphine and antiretrovirals I: Non-nucleoside reverse transcriptase inhibitors I: Efavirenz and delavirdine. Clin Infect Dis. 2006 43 (Suppl 4 S224 234.
11. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993 37 : 178 182.
12. Arroyo E, Valenzuela B, Portilla J, et al. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol. 2007 63 : 669 675.
13. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002 72 : 1 9.
14. Kuhlman JJ Jr., Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998 93 : 549 559.
15. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 191 : 825 829.
16. de Maat MM, Beijnen JH, Schellens JH, et al. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. J Infect. 2005 50 (3 262 264.
17. Handlesman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opioid withdrawal. Am J Drug Alcohol Abuse. 1987 13 : 293 308.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 12 : 189 198.
19. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006 28 : 245 251.
20. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B. 2003 791 : 137 147.
21. WinNonlin Professional computer program Version 3.2. Mountain View, CA.
22. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict. DOI : 10.1111/j.1521-0391.2009. 00005.x.
23. Physicians' Desk Reference: Viramune (nevirapine). 2007 61 : 873 878.
24. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 9 : 365 373.
25. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008 108 : 363 374.
26. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999 36 : 289 304.
27. Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 48 : 4148 4153.
28. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001 33 : 1595 1597.
29. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007 320 : 72 80.
30. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999 27 : 895 901.
31. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006 34 : 440 448.
32. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994 55 : 569 580.
33. Cowan A, Lewis JW. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York, NY : Wiley-Liss 1995.
34. Cone E, Gorodetzky C, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984 12 : 577 581.
35. Ferrari A, Coccia CP, Bertolini A, et al. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 50 : 551 559.
36. Jones ES, Moore BA, Sindelar JL, O'Connor PG, et al. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009 99 : 132 140.